Strides successfully concludes USFDA inspection at Singapore facility
Advertisement
Bengaluru: Strides Pharma Science Limited has announced that its formulation facility at Singapore underwent a US Food and Drug Administration (USFDA) inspection that ended on August 8, 2022.
The inspection was completed successfully with Zero 483 observations. US is one of the key focus markets for Strides and the company has given a growth outlook of US$250m in FY23 for the US business. The company has set a target to launch ~ 20 new products every year in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.